1. <optgroup id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></optgroup>
    <cite id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></cite>
      1. <legend id="wrmvh"></legend>

        <ol id="wrmvh"></ol>

          1. <strong id="wrmvh"></strong>
          2. <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <optgroup id="wrmvh"></optgroup>
            <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <span id="wrmvh"><sup id="wrmvh"><object id="wrmvh"></object></sup></span>
            1. <span id="wrmvh"><video id="wrmvh"></video></span>
              <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
              <strong id="wrmvh"></strong>
              <legend id="wrmvh"><i id="wrmvh"></i></legend>
              1. <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
                1.  
                   
                   
                   
                   
                  臨床PI
                  郭小毛 教授
                  教授,博士生導師
                  E-mail: guoxm1800@126.com
                   

                    1993年畢業于上海醫科大學獲腫瘤學碩士學位,2009年赴美國M.D.安德森腫瘤中心做訪問學者。擅長于乳腺腫瘤和腹部腫瘤的放射治療,尤其在乳腺癌、前列腺癌等腫瘤疾病的放射治療及綜合治療方面有較深入的研究。現任復旦大學附屬腫瘤醫院院長、上海市質子重離子醫院(復旦大學附屬腫瘤醫院質子重離子中心)院長,中國抗癌協會副理事長、中國抗癌協會腫瘤放射治療專業委員會候任主任委員。曾承擔多個市級科委科研項目及國家自然科學基金。先后在國內外腫瘤權威雜志發表論文60余篇。


                  研究領域:

                    1.乳腺癌的臨床與轉化性研究
                     開展早期乳腺癌保乳術后部分乳腺照射、全乳大分割放療、乳腺癌粒子治療等前瞻性研究;著力于前列腺癌和乳腺癌轉化性研究,尤其在不同分子分型的乳腺細胞的放療敏感性差異及放射增敏劑應用等方面有著深入研究。
                    2.質子重離子的臨床與轉化性研究
                    質子和重離子放療是目前最尖端的放療技術。復旦大學附屬腫瘤醫院質子重離子中心/上海市質子重離子醫院于2015年5月正式投入使用,是國際上第三個同時擁有質子和重離子放療系統的醫療單位,目前已治療各類腫瘤患者千余例。著眼于“精準醫療”,以乳腺癌和前列腺的質子、重離子放療技術臨床個體化應用為核心,明確基于生物影像和組學特征譜的多線束精準放療的適應人群。


                  研究團隊:



                  代表性論著:

                  1. Zhou ZR#, Wang CC, Sun XJ, Yang ZZ, Chen XX, Shao ZM, Yu XL*, Guo XM*. Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. Cancer Medicine, 2018; 7(4):1030–1042.
                  2. Zhou ZR#, Yang ZZ, Yu XL*, Guo XM*. Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects. Cancer Medicine, 2018; 7:3110–3117.
                  3. Zhou ZR#, Yang ZZ#, Wang SJ, Zhang L, Luo JR, Feng Y, Yu XL, Chen XX*, Guo XM*. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. Acta Pharmacologica Sinica, 2017; 38(4):513-523.
                  4. Chen XX#, Ma NY#, Zhou ZR#, Luo JR, Mei X, Yang ZZ, Zhang L, Wang XF, Feng Y, Yu XL, Ma JL*, Guo XM*. Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells. Medical Science Monitor, 2017; 1;23:2674-2683.
                  5. Hou J#, Zhou ZR#, Chen XX#, Zhao RP, Yang ZZ, Wei N, Ni Q, Feng Y, Yu XL, Ma JL*, Guo XM*. HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. Oncotarget, 2016; 7(29):45186-45198.
                  6. Hu QC#, Mei X#, Feng Y, Ma JL, Yang ZZ, Shao ZM, Yu XL*, and Guo XM*. Early Local Recurrence Presents Adverse Effect on Outcomes of Primary Breast Sarcoma A Retrospective Study From Single Institute in China. Medicine, 2016; 95(1): e2422.
                  7. Zhou ZR#, Mei X#, Chen XX, Yang ZZ, Hou J, Zhang L, Yu XL*, Guo XM*. Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer. Surgical oncology, 2015; 24(3):200-211.
                  8. Zhang L#, Yang ZZ#, Chen XX#, Tuan J, Ma JL, Mei X, Yu XL, Zhou ZR, Shao ZM, Liu GY*, Guo XM*. Dose coverage of axillary level I-III areas during whole breast irradiation with simplified intensity modulated radiation therapy in early stage breast cancer patients. Oncotarget, 2015; 6(20):18183-18191.
                  9. Qi WX, Fu S*, Zhang Q and Guo XM. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. Journal of chemotherapy, 2015; 27(3):181-187.
                  10. Zhang Q#, Yu XL#, Hu WG, Chen JY, Wang JZ, Ye JS and Guo XM*. Dosimetric comparison for volumetric modulated arc therapy and intensity-modulated radiotherapy on the left-sided chest wall and internal mammary nodes irradiation in treating post-mastectomy breast cancer. Radiology and oncology, 2015 Mar 3; 49(1):91-98.
                  11. Qi WX, Fu S*, Zhang Q and Guo XM*. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC medicine, 2014 Nov 5; 12:203.
                  12. Wang X, Li L, Liang Y, Li C, Zhao H, Ye D, Sun M, Jeong LS, Feng Y, Fu S, Jia L*, Guo X*. Targeting the neddylation pathway to suppress the growth of prostate cancer cells: therapeutic implication for the men's cancer. Biomed Res In, 2014; 2014:974309.
                  13. Wang ZL#, Hou J#,Lu LL, Qi ZH, Sun JM, Gao W, Meng J, Wang Y, Sun HZ, Gu HY, Xin YH, Guo XM*, Yang G*. Small Ribosomal Protein Subunit S7 Suppresses Ovarian Tumorigenesis through Regulation of the PI3K/AKT and MAPK Pathways. Plos ONE, 2013 Nov 11; 8(11):e79117.
                  14. Chen X, Yu X, Chen J, Yang Z, Shao Z, Zhang Z, Guo X*, Feng Y. Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist, 2013; 18(2):141-147.
                  15. Chen X, Yu X, Chen J, Zhang Z, Tuan J, Shao Z, Guo X*, Feng Y. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors. Cancer, 2013; 119(13):2366-2374.
                  16. Yang Z, Chen J, Xie J, Zhu C, Pan Z, Yu X, Mei X, Fu X, Guo X*. Simultaneous integrated boost in breast conserving radiotherapy: is replanning necessary following tumor bed change. Technology in Cancer Research and Treatment, 2013; 12(2):115-122.
                   
                  復旦大學腫瘤研究所 通訊地址: 東安路270號2號樓1312室 64175590-5312 Email:fuci2012@126.com
                  Copyright 2013 shca.org.cn All rights reserved. 復旦大學腫瘤研究所 版權所有
                  小草在线观看视频播放免费 青青草久2019在线视频| 免费强奷视频网站| 快看影院kuaikanyy| 瑞典嫩草的香味儿在线播放电影| 青青青在线视频大杳蕉| 豆奶app m.emu999.net| 快看影院app在线下载 迅雷下载安装| 热机久久视频在线视频15| 啪啪啪小视频| 婷婷六月丁香综合基地| 处理公司女经理电影2018|